Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer (original) (raw)
Abstract
The distribution of iodine-131 (131I) labelled antibody to carcinoembryonic antigen (CEA) has been studied in 16 patients with colorectal cancer. Levels of tumour and normal tissue radioactivity were measured by serial gamma-camera imaging and counting of blood and urine. Maximum concentrations were found in tumour 8 h after administration and varied up to 9-fold in different patients. Higher levels were found on average in tumour than in any other tissue. Liver, lung and blood were the other tissues in which antibody was concentrated relative to the rest of the body. Antibody cleared from all these tissues over 1 week. Second antibody directed against the antitumour (first) antibody was given 24 h after first antibody in order to accelerate clearance from the blood. This increased the tumour to blood ratio but had little effect on other tissues. Cumulative radiation dose to tumour and normal tissue was estimated. In patients with the most efficient localisation the tumour to body ratio was 20:1 and tumour to blood ratio 5:1. This may be sufficient for effective therapy of cancer in patients selected for efficient antibody localisation. The data may be used to estimate the effect of different therapeutic strategies. For instance, in the time after second antibody administration the average tumour to blood ratio of radiation dose was 11:1, suggesting that two phase systems in which the therapeutic modality is given after a good tumour to normal tissue ratio is obtained may be effective for the majority of patients.
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Similar content being viewed by others
Author information
Authors and Affiliations
- Department of Medical Oncology, Charing Cross and Westminster Medical School, London, UK
RHJ Begent
Authors
- RHJ Begent
- JA Ledermann
- AJ Green
- KD Bagshawe
- SJ Riggs
- F Searle
- PA Keep
- T Adam
- RG Dale
- MG Glaser
Rights and permissions
About this article
Cite this article
Begent, R., Ledermann, J., Green, A. et al. Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer.Br J Cancer 60, 406–412 (1989). https://doi.org/10.1038/bjc.1989.295
- Issue date: 01 September 1989
- DOI: https://doi.org/10.1038/bjc.1989.295
This article is cited by
Fractionated 131I anti-CEA radioimmunotherapy: effects on xenograft tumour growth and haematological toxicity in mice
- J A Violet
- J L J Dearling
- R B Pedley
British Journal of Cancer (2008)
Current status of cancer therapy with radiolabeled monoclonal antibody
- Noboru Oriuchi
- Tetsuya Higuchi
- Keigo Endo
Annals of Nuclear Medicine (2005)
Current status and future directions of radioimmunotherapy
- J. Tschmelitsch
European Surgery (1999)
- J. Tschmelitsch
Clinical evidence of efficient tumor targetting based on single–chain Fv antibody selected from a combinatorial library
- R.H.J. Begent
- M.J. Verhaar
- L. Robson
Nature Medicine (1996)
The value of radioimmunoguided surgery in first and second look laparotomy for colorectal cancer
- P. M. Dawson
- S. D. Blair
- N. A. Theodorou
Diseases of the Colon & Rectum (1991)